As a life sciences strategy consultant, Anne answers strategy questions for biotech and pharma companies. She has experience in strategic forecasting, opportunity assessments, franchise-level acquisition strategy, pricing and market access, buy-side due diligence, and indication prioritization. Anne’s expertise is primarily in novel therapeutics, with modest experience in medical devices.
Anne is also experienced in evaluating precision medicine options for oncology patients, and facilitating conversations regarding possible personalized treatment approaches and clinical trial options.
Anne holds a Ph.D. from Harvard University in biological chemistry and molecular pharmacology, and a BA from Oberlin College. She is a native Portlander who currently lives in Boston, MA.
“I can help refine ideas and offer advice regarding clinical and commercial development strategies. This includes discussion of target patient populations, trial design strategies, potential payer management of new therapies, and competitive positioning.”